Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MPLX LP (MPLX) vs Viatris Inc (VTRS) Price & Performance

Viatris IncTrade

Price performance (Past 24H)

Key statistics

MPLX LP vs Viatris Inc — how do they compare? MPLX LP trades at $60.05 (market cap $60.66B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: MPLX LP is far larger — about 3.2× Viatris Inc's market cap, and MPLX LP pays the higher dividend (7.2%). Which is the better fit depends on your goals.

MPLXVTRS
Market Cap
$60.66B$19.09B
Sector
TechnologyHealth
52-Week High
$60.51$17.86
52-Week Low
$47.80$9.49
Enterprise Value
$85.76B$31.21B
Dividend Yield
7.2%2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MPLX LP

MPLX trades at $59.83, up 0.27% with strong technical momentum as moving averages signal bullish conditions. The company demonstrates robust profitability with 40.45% net income margin and 33.95% ROE, though recent Q2 2026 earnings matched expectations without beating. Analyst consensus remains strongly bullish with 19 buy ratings and a $64.00 price target, representing 7% upside potential. Recent news highlights management's commitment to 12.5% annual distribution growth through 2027.

MPLX offers attractive income with 7%+ yield and distribution growth potential, supported by fee-based midstream operations. Key risks include rising leverage approaching 4x and exposure to energy market volatility. The stock presents a compelling value proposition for income-focused investors seeking energy infrastructure exposure with growth catalysts from ongoing capacity expansions.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MPLX LP

MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.

Read more on MPLX

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS